Synmosa Biopharma Corporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 1,057.73 million compared to TWD 778.15 million a year ago. Net income was TWD 401.26 million compared to TWD 76.04 million a year ago. Basic earnings per share from continuing operations was TWD 1.1346 compared to TWD 0.2104 a year ago. Diluted earnings per share from continuing operations was TWD 1.1254 compared to TWD 0.2104 a year ago.
For the six months, sales was TWD 2,024.4 million compared to TWD 1,538.49 million a year ago. Net income was TWD 526.4 million compared to TWD 137 million a year ago. Basic earnings per share from continuing operations was TWD 1.4731 compared to TWD 0.3843 a year ago. Diluted earnings per share from continuing operations was TWD 1.4731 compared to TWD 0.3843 a year ago.